Log in

NASDAQ:ALPNAlpine Immune Sciences Stock Price, Forecast & News

$10.40
-0.19 (-1.79 %)
(As of 08/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.16
Now: $10.40
$10.66
50-Day Range
$8.98
MA: $10.12
$12.10
52-Week Range
$2.05
Now: $10.40
$15.00
Volume59,629 shs
Average Volume109,346 shs
Market Capitalization$193.34 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.
Read More
Alpine Immune Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALPN
CUSIPN/A
Phone206-788-4545

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.74 million
Book Value$1.59 per share

Profitability

Net Income$-41,850,000.00
Net Margins-1,236.45%

Miscellaneous

Employees48
Market Cap$193.34 million
Next Earnings Date8/11/2020 (Confirmed)
OptionableNot Optionable
$10.40
-0.19 (-1.79 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALPN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions

How has Alpine Immune Sciences' stock been impacted by COVID-19 (Coronavirus)?

Alpine Immune Sciences' stock was trading at $2.91 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ALPN stock has increased by 257.4% and is now trading at $10.40.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Alpine Immune Sciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Alpine Immune Sciences
.

When is Alpine Immune Sciences' next earnings date?

Alpine Immune Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for Alpine Immune Sciences
.

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences Inc (NASDAQ:ALPN) announced its quarterly earnings data on Thursday, May, 14th. The biotechnology company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.17. The biotechnology company had revenue of $1.09 million for the quarter, compared to analysts' expectations of $0.38 million. Alpine Immune Sciences had a negative net margin of 1,236.45% and a negative return on equity of 104.04%.
View Alpine Immune Sciences' earnings history
.

What price target have analysts set for ALPN?

5 equities research analysts have issued twelve-month target prices for Alpine Immune Sciences' shares. Their forecasts range from $8.00 to $22.00. On average, they anticipate Alpine Immune Sciences' stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 53.8% from the stock's current price.
View analysts' price targets for Alpine Immune Sciences
.

Has Alpine Immune Sciences been receiving favorable news coverage?

News stories about ALPN stock have been trending somewhat negative recently, InfoTrie reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Alpine Immune Sciences earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Alpine Immune Sciences
.

Are investors shorting Alpine Immune Sciences?

Alpine Immune Sciences saw a increase in short interest in January. As of January 15th, there was short interest totaling 23,700 shares, an increase of 20.9% from the December 31st total of 19,600 shares. Based on an average trading volume of 20,800 shares, the days-to-cover ratio is presently 1.1 days. Currently, 0.3% of the company's stock are sold short.
View Alpine Immune Sciences' Short Interest
.

Who are some of Alpine Immune Sciences' key competitors?

What other stocks do shareholders of Alpine Immune Sciences own?

Who are Alpine Immune Sciences' key executives?

Alpine Immune Sciences' management team includes the following people:
  • Dr. Mitchell H. Gold, Exec. Chairman & CEO (Age 51)
  • Dr. Stanford Peng, Pres and Head of R&D (Age 48)
  • Mr. Paul Rickey, Sr. VP, CFO & Corp. Sec. (Age 40)
  • Dr. Kristine Swiderek Ph.D., Sr. VP of Research

What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Berman Capital Advisors LLC (0.29%). Company insiders that own Alpine Immune Sciences stock include James N Topper, James Paul Rickey, Mitchell Gold and Tiger Management LLC.
View institutional ownership trends for Alpine Immune Sciences
.

Which institutional investors are buying Alpine Immune Sciences stock?

ALPN stock was acquired by a variety of institutional investors in the last quarter, including Berman Capital Advisors LLC. Company insiders that have bought Alpine Immune Sciences stock in the last two years include James N Topper, James Paul Rickey, and Mitchell Gold.
View insider buying and selling activity for Alpine Immune Sciences
.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $10.40.

How big of a company is Alpine Immune Sciences?

Alpine Immune Sciences has a market capitalization of $193.34 million and generates $1.74 million in revenue each year. The biotechnology company earns $-41,850,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. Alpine Immune Sciences employs 48 workers across the globe.

What is Alpine Immune Sciences' official website?

The official website for Alpine Immune Sciences is www.alpineimmunesciences.com.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.